BEIJING, Nov. 11, 2025 /PRNewswire/ — Autozi Internet Technology (Global) Ltd. (“Autozi” or the “Company”) (Nasdaq: AZI), one of China’s leading and fastest-growing lifecycle automotive service and supply-chain technology platforms, today announced the launch of its new business strategy to drive the next phase of growth and globalization.

The strategy establishes a scalable platform for sustainable growth built on three core pillars:  Capitalization, Digitalization, and Globalization. Leveraging its public company platform, Autozi will acquire and integrate high-quality enterprises, enhance them through its proprietary SaaS-based supply-chain system, and expand their reach into global markets. This unified digital ecosystem connects manufacturers, distributors, and service providers across the automotive value chain to enable smarter operations, higher efficiency, and greater transparency.

The framework is adaptable across multiple sectors, with initial focus on two high-growth verticals: EV Core Components and Special-Purpose Vehicles (SPVs). Autozi is accelerating its entry into EV core components, targeting powertrain, battery management, and thermal system companies. Through its S2M2B (Supplier-to-Manufacturer-to-Business) supply-chain model, Autozi links suppliers, OEMs, and aftermarket partners to enable real-time coordination of orders, payments, and logistics — creating a digital backbone for the rapidly expanding EV ecosystem.

In parallel, Autozi is building a Special-Purpose Vehicle Group, integrating leading SPV manufacturers across emergency, utility, and logistics vehicle categories. Using the same digital platform, Autozi connects suppliers, OEMs, and service networks to optimize operations from production to maintenance. Strategic M&A, governance enhancements, and technology upgrades will help modernize the fragmented SPV sector and support Chinese brands expanding globally.

Autozi believes the new strategy positions the Company for stronger, more sustainable growth in the global mobility landscape. By combining industrial integration with digital intelligence, Autozi aims to build a multi-segment growth platform that delivers long-term value, operational excellence, and global competitiveness.

About Autozi Internet Technology (Global) Ltd.

Autozi Internet Technology (Global) Ltd. is a leading, fast-growing provider of lifecycle automotive services in China. Founded in 2010, Autozi offers a comprehensive range of high-quality, affordable, and professional automotive products and services through both online and offline channels across the country. Leveraging its advanced online supply chain cloud platform and SaaS solutions, Autozi has built a dynamic ecosystem that connects key participants across the automotive industry. This interconnected network enables more efficient collaboration and streamlined processes throughout the entire supply chain, positioning Autozi as a key driver of innovation and growth in the automotive services sector.

Forward-Looking Statements

All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. These forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, as actual results may be impacted by a variety of factors, including without limitation, changes in macroeconomic conditions, industry dynamics, competitive landscape, regulatory requirements, the Company’s ability to successfully implement its growth strategies and effectively manage costs and operations, and unforeseen business challenges. The Company encourages investors to review other factors that may affect its future results in the Company’s registration statement, periodic reports, including its Annual Report on Form 20-F and Current Report on Form 6-K, and in its other filings with the SEC.

Contact Information

Autozi Internet Technology (Global) Ltd.
Ms. Jiabing Song
Email: boardoffice@autozi.com 

SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ — Petnow Inc., a leading AI-based pet biometrics technology company, announced that it has signed a Memorandum of Understanding (MOU) with Pet Biometrics Corp., a U.S.-based company, to jointly pursue opportunities in the North American public sector. The partnership will support participation in government procurement programs for pet identification, registration, and licensing projects across major U.S. cities.

The agreement establishes a strategic collaboration framework to jointly respond to government RFPs (Requests for Proposals), beginning with New York City and expanding to other key municipalities nationwide. Pet Biometrics Corp. will serve as the local operational arm, focusing on regulatory compliance, relationship development with local and federal agencies, and preparation of competitive proposals for pet identification programs.

This partnership represents a significant step for Petnow as it strengthens its presence in the U.S. pet tech sector, particularly within the emerging field of digital pet identity and verification.

Under the collaboration, Petnow will provide its core biometric identification technologies, including nose print recognition for dogs, facial recognition for cats, and system integration and data management capabilities. Proven and commercialized across Asia, these AI-powered solutions will be localized to meet U.S. public sector standards, enhancing accuracy, duplication prevention, and data integrity in pet registration systems.

“Our collaboration with Pet Biometrics Corp. provides a structured pathway into the U.S. public market, starting with New York City,” said Joonho Lim, CEO of Petnow Inc. “This agreement marks the beginning of a long-term partnership that may evolve into a joint venture to better serve the North American pet ecosystem.”

About Petnow Inc.

Petnow Inc. has commercialized smartphone-based biometric recognition technology that identifies pets using dog nose prints and cat facial patterns. Its Petify platform enables secure digital identification for pet registration, loss prevention, insurance data verification, and veterinary record management. Petnow is building a global digital pet ID infrastructure to connect public and private systems, advancing safety, accountability, and trust in pet ownership worldwide.

New Collaboration Offers Customers Stylish Technology Products Curated with Female Gamers in Mind

LOS ANGELES, Nov. 11, 2025 /PRNewswire/ — SHEIN, the global online fashion and lifestyle retailer, today announced a new partnership with Newegg, Inc. (NASDAQ: NEGG), a global e-commerce leader for technology products. The Newegg storefront on SHEIN’s U.S. site will feature more than 1,000 technology products curated for gamers who prioritize personal style when purchasing the latest technology products.

SHEIN’s Newegg storefront blends fashion and technology, offering customers new ways to express individuality through their devices, accessories, and home setups. From powerful gaming laptops and sleek ultrabooks to discreet earbuds and bold over-ear headphones, the assortment highlights how technology has become as much a style choice as a functional necessity. Newegg, known worldwide for its broad selection of PC components, lets customers build systems to match their style preferences, from case design to cooling systems.

“Technology is deeply personal – it’s how people work, play, and express themselves,” said Katie Lau, director of corporate marketing at Newegg. “This collaboration with SHEIN creates a unique opportunity to bridge fashion and technology, showing how everything from your gaming setup to your earbuds can become part of your personal identity.”

According to a 2025 study from Euromonitor International, women are central to the gaming industry, with 38% of online female consumers playing weekly and driving growth across games, content, and related lifestyle products. For SHEIN and Newegg, this shift represents a chance to meet rising demand and connect with a generation that embraces fashion, lifestyle, and technology.

“We’re excited to partner with Newegg to offer customers innovative products that reflect their passions and enhance their lifestyles,” said George Chang, general manager and head of SHEIN Marketplace U.S. “With growing customer demand, SHEIN is evolving into a go-to destination for lifestyle products, with a focus on accessibility and self-expression.”

SHEIN’s Newegg online storefront is now available and features a curated range of finished tech products. The selection will be updated seasonally, reflecting emerging trends and customer demand.

SHEIN Marketplace is committed to continuing to provide sellers with the tools, resources, and support needed to set them up for success and is onboarding new sellers to meet the needs of its growing customer base; more information for prospective sellers can be found here.

About Newegg

Newegg, Inc. (NASDAQ: NEGG), headquartered in City of Industry, Calif., is a leading global e-commerce company focused on technology, electronics, gaming, and lifestyle products. Founded in 2001, Newegg provides direct-to-consumer and B2B solutions across North America, Europe, Asia Pacific, Latin America, and the Middle East. For more information, visit www.newegg.com.

About SHEIN

SHEIN is a global online fashion and lifestyle retailer, offering SHEIN branded apparel and products from a global network of vendors, all at affordable prices. SHEIN remains committed to making the beauty of fashion accessible to all, promoting its industry-leading, on-demand production methodology, for a smarter, future-ready industry. To learn more about SHEIN, visit www.sheingroup.com.

SHANGHAI, Nov. 11, 2025 /PRNewswire/ — Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes.

This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development, while Yugong Bio holds core advantages in enzyme engineering and large-scale production. This powerful alliance will focus on the entire chain of enzyme product R&D, production, and application. By seamlessly integrating their respective superior resources, the partners aim to jointly overcome key technological bottlenecks in the biopharmaceutical field, committed to driving cost reduction, efficiency improvement, and technological innovation across the industry. This forward-looking strategic layout not only marks a new phase for the collaboration but also injects fresh momentum into the high-quality development of China’s biopharmaceutical industry.

Powerful Synergy: Complementary Strengths Form a Solid Foundation for Cooperation

Sanyou Bio is a biotechnology company focused on the discovery and development of innovative antibody drugs. Its internationally leading ultra-trillion-scale antibody library, combined with the dual drivers of “Efficient Screening + AI Analysis,” forms a powerful drug discovery engine. This platform enables rapid screening from massive libraries to precise candidates, significantly accelerating early-stage drug discovery and providing solid foundational innovation for R&D. This unique advantage injects a powerful “source of innovation” into early drug R&D, with its vast library capacity and exceptional screening efficiency already becoming an industry tool for accelerating drug discovery.

Yugong Bio is a national high-tech enterprise focusing on upstream molecular enzyme reagents for synthetic biology and their application solutions. The company possesses strong capabilities in enzyme molecular engineering and cell-free protein synthesis. Its enzyme products are renowned for high purity, high activity, and high stability, widely used in basic life science research, biopharmaceutical production, and bio-industrial fields, offering highly differentiated competitive advantages. Leveraging its deep expertise in enzyme engineering, Yugong Bio provides customers with stable, reliable, and cost-effective enzyme-related products and services.

Collaborative Win-Win: Strategic Cooperation Opens a New Future

This strategic collaboration is based on both parties’ profound understanding of industry trends and high recognition of each other’s technical capabilities. It aims to create core value through deep synergy across three levels:

1.  Resource Complementarity: Building End-to-End Capability from “Discovery” to “Delivery”: Sanyou Bio will utilize its trillion-scale molecular library and efficient screening platform to support Yugong Bio’s enzyme optimization and engineering for specific application scenarios. Yugong Bio will leverage its mature enzyme product R&D and large-scale production system to ensure the quality and stable supply of co-developed products. This integrated “Discovery + Optimization + Production” model will greatly accelerate the R&D industrialization process.

2.  Market Win-Win: Creating Cutting-Edge Products with Better Cost-Effectiveness: Through joint R&D and supply chain coordination, the partners aim to develop enzyme preparations and solutions with superior performance and lower cost. This will not only help reduce the R&D and production costs for both parties but also provide more cost-effective products for downstream customers, especially in fields like biopharmaceutical R&D and in vitro diagnostics, enhancing their market competitiveness.

3.  Industry Empowerment: Catalyzing Next-Generation Innovative Solutions: This collaboration represents a deep integration of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. It holds the potential to catalyze a batch of innovative enzyme products and solutions that lead the future, injecting new momentum into the entire biopharmaceutical industry.

Dr. David Lang, Founder and CEO of Sanyou Bio, stated: “The collaboration with Yugong Bio represents a deep coupling of cutting-edge molecular discovery capabilities and advanced enzyme engineering technology. We firmly believe that this strategic synergy will go beyond simple addition of advantages, transcend single, isolated R&D efforts, and create a seamlessly connected value loop, thereby accelerating scientific innovation and the commercial success of branded products.”

Dr. Henghao Xu, Founder and CEO of Yugong Bio, stated: “The strategic collaboration with Sanyou Bio is a significant step in Yugong Bio’s development journey. Sanyou’s exceptional capabilities in ultra-large capacity molecular libraries and screening will inject strong momentum into the foundational innovation of our enzyme products. We are confident that through close cooperation, we can bring more breakthrough products to the market, achieving win-win development.”

The strategic collaboration between Sanyou Bio and Yugong Bio is not merely a powerful alliance of complementary strengths but also a key milestone, marking a solid step forward in their journey to deepen industrial synergy and build core technological barriers.

About Yugong Bio

Jiangsu Yugong Biotechnology Co., Ltd. primarily addresses the “bottleneck” situation of upstream molecular enzyme raw materials in domestic synthetic biology and biopharmaceuticals, committed to providing more high-quality, economical, user-friendly enzyme products with independent intellectual property rights. The company headquarters is located in the China (Jiangsu) Pilot Free Trade Zone Lianyungang Area, constructed and managed with reference to GMP standards; its wholly-owned subsidiary Jiangsu Baisimei Biotechnology Co., Ltd., located in the Lianyungang National High-Tech Zone, is mainly responsible for R&D and research reagent production. The company adheres to independent R&D as its core and has established domestically leading cell-free protein synthesis and toxic protein recombinant expression technology platforms. It has been certified as a National High-Tech Enterprise and has obtained ISO13485 Quality Management System certification.

The company was the first in China to achieve large-scale production of the DNA “molecular scissors” – restriction endonucleases, breaking the complete monopoly of foreign companies for over 40 years. It currently ranks among the top three in the domestic restriction enzyme market share and has entered the supply chains of several leading domestic synthetic biology upstream enterprises. The company now possesses over 100 products across 11 series including restriction enzymes, cell-free protein synthesis, modification & cloning, PCR, isothermal amplification, reverse transcription, quantitative real-time PCR, and in vitro transcription, widely used in gene synthesis, molecular diagnostics, biomedical research, and other fields.

About Sanyou Bio

Sanyou Bio is a high-tech biopharmaceutical enterprise driven by its mission to “Enable Easy Innovation of Biologics for All” and powered by its ultra-trillion-scale molecular libraries and intelligent technology.

The company is dedicated to building a globally top-tier original innovation factory for new drugs. It centers on the AI-powered Super-Trillion Antibody Library (AI-STAL); relies on its integrated, intelligent, and internationally leading innovative biologics R&D platform combining in silico and wet-lab approaches; and promotes the R&D and industrialization of global innovative drugs through diversified business models.

The company is headquartered in Shanghai, China, and has established business centers in Asia, North America, Europe, and other regions, forming a global business network. It currently has over 20,000 square meters of R&D and GMP facilities in operation or under development.

The company has established sound cooperative relationships with over 2,000 pharmaceutical companies and biotechnology firms globally, has empowered more than 1,200 new drug R&D projects, and has completed over 50 cooperative R&D projects, more than 10 of which have advanced to the IND and clinical development stages.

The company has filed for over 130 invention patents, more than 30 of which have been granted. It has also obtained over 10 qualifications and system certifications including National High-Tech Enterprise, Shanghai Specialized, Refined, Distinctive, and New (SRDN) Enterprise, ISO9001, and ISO27001.